Search

Displaying results 2591 - 2600 of 8196 in total
  1. Drug

    Rolapitant

    go.drugbank.com/drugs/DB09291
    ApprovedInvestigational

    Neurokinin-1 is also known as Tachykinin Receptor 1 (TACR1), Neurokinin 1 Receptor (NK1R), and Substance P Receptor (SPR). … By blocking Substance P from interacting with NK-1 receptors in the gut and the central nervous system, rolapitant prevents late-phase CINV.

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 Substrates
  2. Drug

    Indacaterol

    go.drugbank.com/drugs/DB05039
    ApprovedInvestigational

    Indacaterol is a novel, ultra-long-acting, rapid onset β(2)-adrenoceptor agonist developed for Novartis for the once-daily management of asthma and chronic obstructive pulmonary disease. It was approved by the European Medicines Agency (...

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  3. Drug

    Tasimelteon

    go.drugbank.com/drugs/DB09071
    ApprovedInvestigational

    In blind individuals, a lack of light stimulation causes an extension of the 24-hour circadian cycle and can lead to progressively delayed sleep onset.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates
  4. Drug

    Temocapril

    go.drugbank.com/drugs/DB08836
    Investigational

    Temocapril can also be used in hemodialysis patients without risk of serious accumulation.

  5. Drug

    Laropiprant

    go.drugbank.com/drugs/DB11629
    ApprovedWithdrawn

    Laropiprant is an ingredient in the EMA-withdrawn product Pelzont.

  6. Drug

    Ticarcillin

    go.drugbank.com/drugs/DB01607
    ApprovedVet approvedWithdrawn

    An antibiotic derived from penicillin similar to carbenicillin in action.

  7. Drug

    Deucravacitinib

    go.drugbank.com/drugs/DB16650
    ApprovedInvestigational

    [A246938, A246943] This selectivity towards TYK2 may lead to an improved safety profile of deucravacitinib, as nonselective JAK inhibitors are associated with a range of adverse effects such as altered

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  8. Drug

    Protriptyline

    go.drugbank.com/drugs/DB00344
    Approved

    The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. … They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, protriptyline does not affect mood or arousal, but may cause sedation.

    Synonyms: 5-(3-methylaminopropyl)-5H-dibenzo[a,d]cycloheptene, 3-(5H-dibenzo[a,d][7]annulen-5-yl)-N-methylpropan-1-amineCategories: P-glycoprotein inhibitors
  9. Target

    Relaxin receptor 1

    go.drugbank.com/bio_entities/BE0019700
    TargetHumans

    Receptor for relaxins. The activity of this receptor is mediated by G proteins leading to stimulation of adenylate cyclase and an increase of cAMP. Binding of the ligand may also activate a tyrosine kinase pathway that inhibits the activ...

    Synonyms: Leucine-rich repeat-containing G protein-coupled receptor 7
  10. Drug

    Oxyphenbutazone

    go.drugbank.com/drugs/DB03585
    ApprovedWithdrawn

    Oxyphenbutazone was withdrawn from the Canadian market in March 1985 due to concerns regarding bone marrow suppression.